ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.
about
The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients.Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.Predominance of ERG-negative high-grade prostate cancers in African American men.Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate TumorsSpecific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contextsCharacterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG.ERG protein expression as a biomarker of prostate cancer.Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomymiRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.Ecotropic viral integration site 1, a novel oncogene in prostate cancer.Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancerPrognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.Ethnicity and ERG frequency in prostate cancer.Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
P2860
Q33876961-52402A7F-7FB9-4F71-98CE-3D94335B151FQ34036819-DB5FA6BB-0083-48C3-B0F3-2A17E0C5F834Q34265721-223DDBF5-FF09-4727-BD6A-6F5369D167CAQ35125405-971D82E2-5DA3-48C6-BB14-B964534EE778Q35631603-47B5249D-2B98-4238-8196-1F6377B48CB7Q35741647-4D88973F-4C02-4690-92FB-38BD53A92594Q36035812-E3DD947E-E163-48B4-B71C-7F14CA0306C4Q36291246-E94A18A1-2B78-460B-A476-358ED0666A04Q37046014-E1BB1BA3-0242-4329-BB04-B3D314F110D8Q37139054-89369870-FF8F-4373-8EC6-95203D5B101EQ37669712-8CDE2886-25A3-464D-88CC-3B1D7DA3471BQ38165243-F3CF55FC-7BC5-4FB4-B802-3F63110CAC80Q38391360-3617481E-AA29-49C3-91A4-19FB622C7B7DQ38794624-B7FDCE9C-FF70-44E5-9788-634C7975FE55Q39214638-C8DE8719-BF15-421C-AB33-FC373BC14524Q39401617-A9FA7480-5E69-45EF-A9ED-28DDB812AD62Q40322483-EDBF20AF-7689-45FC-B621-5D8A024CDD81Q40335169-A9E0944D-3ADC-4F74-A486-69D5CBD243D3Q41132392-DE562852-BAB3-4DAD-975C-25CE4287184FQ41660235-2C236F4E-A37F-41B3-A36E-DC7D519B4F4AQ41733293-DB4B7FA1-C0A4-41CA-9E5A-00D386AC90AEQ41951871-86E3DBFA-4E94-4CAA-A330-05C8C6C90DFEQ41988183-45C379C8-325C-4426-BD9D-A3513FD5230EQ42287150-6C4FD1B1-29A4-46EC-8FFA-B8801A100839Q42539779-680D7B35-3C75-419E-BFCE-0F46C84C2A3FQ42748239-9166D972-0200-480F-9FAB-352AA2965B3CQ42782654-D28C15B0-9A29-473A-89B3-CE85E1A1621DQ43269413-CEAF56F4-46C4-4170-A318-62AD1E2A2392Q46504038-85D7638B-233C-4862-A49C-A33B7BA301B8Q47355331-7932C46E-218E-4080-8FB0-210C09DF0589Q48087902-23509DE3-A986-4744-9142-085B95010520Q51395627-BAC8D87D-E79D-4C5A-BC08-C87A973A6A4FQ53472932-EE666183-DA0C-4E6C-A0E8-74F6A2AEAE7FQ53474669-2D1B5611-E7C5-4096-8CD3-907CB6F6EAE4Q54529907-B3DA459A-389B-45BB-BE18-5E1F42D8B0FD
P2860
ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
ERG protein expression and gen ...... of two monoclonal antibodies.
@en
ERG protein expression and gen ...... of two monoclonal antibodies.
@nl
type
label
ERG protein expression and gen ...... of two monoclonal antibodies.
@en
ERG protein expression and gen ...... of two monoclonal antibodies.
@nl
prefLabel
ERG protein expression and gen ...... of two monoclonal antibodies.
@en
ERG protein expression and gen ...... of two monoclonal antibodies.
@nl
P2093
P2860
P356
P1476
ERG protein expression and gen ...... of two monoclonal antibodies.
@en
P2093
G Kristiansen
P2860
P2888
P304
P356
10.1038/PCAN.2011.67
P577
2012-01-10T00:00:00Z